McCune-Albright syndrome: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(108 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Infobox_Disease |
__NOTOC__
  Name          = McCune-Albright syndrome |
 
  Image          = |
  Caption        = |
  DiseasesDB    = 7880 |
  ICD10          = {{ICD10|Q|78|1|q|65}} |
  ICD9          = {{ICD9|756.54}} |
  ICDO          = |
  OMIM          = 174800 |
  MedlinePlus    = 001217 |
  eMedicineSubj  = ped |
  eMedicineTopic = 1386 |
  MeshID        = D005359 |
}}
{{SI}}
{{SI}}
{{CMG}}; {{AE}} {{Dushka}}
{{CMG}}; {{AE}} [[User:Dushka|Dushka Riaz, MD]]
 
==Overview==
==Overview==


McCune-Albright syndrome is a rare genetic disorder caused by an activating mutation of the GNAS gene resulting in various phenotypic presentations. McCune-Albright syndrome typically presents with the triad of fibrous dysplasia, precocious puberty and café au lait spots in both genders. Other manifestations include hyperthyroidism, acromegaly and Cushing’s syndrome.
McCune-Albright syndrome is a rare genetic disorder caused by an activating mutation of the [[GNAS1|GNAS]] gene resulting in various phenotypic presentations. McCune-Albright syndrome typically presents with the triad of [[fibrous dysplasia]], [[precocious puberty]] and [[Café au lait spot|café au lait]] spots in both genders. Other manifestations include [[acromegaly]], [[Cushing's syndrome|Cushing’s]] syndrome and thyroid hyperplasia or [[toxic nodular goiter]]<nowiki/>s.


==Historical Perspective==
==Historical Perspective==


*McCune-Albright syndrome was first discovered by physicians Donovan McCune and Fuller Albright in 1937.  
*McCune-Albright syndrome was first discovered by physicians [[Donovan McCune]] and [[Fuller Albright]] in 1937. <ref name="pmid21384213">{{cite journal| author=Manring MM, Calhoun JH| title=Biographical sketch: Fuller Albright, MD 1900-1969. | journal=Clin Orthop Relat Res | year= 2011 | volume= 469 | issue= 8 | pages= 2092-5 | pmid=21384213 | doi=10.1007/s11999-011-1831-0 | pmc=3126964 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21384213  }} </ref>


==Classification==
==Classification==
There is no established system for the classification of McCune-Albright syndrome.


==Pathophysiology==
==Pathophysiology==


*The [[pathogenesis]] of McCune-Albright syndrome is characterized by increased [[cAMP]] signaling in [[bone]], [[skin]] and endocrine tissues. In bone osteoblasts differentiation results in fibrous dysplasia. In the skin there is stimulation of melanin production resulting in café au lait macules with irregular borders. In endocrine tissues increased cAMP results in increased production of hormones depending on which tissue is affected including the gonads, thyroid, parathyroid, pituitary and adrenal glands.
*The [[pathogenesis]] of McCune-Albright syndrome is characterized by increased [[cAMP]] signaling in [[bone]], [[skin]] and endocrine tissues. In bone, [[Osteoblast|osteoblasts]] differentiation results in [[fibrous dysplasia]]. In the skin, there is stimulation of [[melanin]] production resulting in [[café au lait macules]] with irregular borders. In endocrine tissues, increased [[Cyclic adenosine monophosphate|cAMP]] results in increased production of [[hormones]] depending on which [[tissue]] is affected including the [[Gonad|gonads]], [[thyroid]], [[Parathyroid gland|parathyroid]], [[Pituitary gland|pituitary]] and [[Adrenal gland|adrenal glands]]. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
*The GNAS gene mutation has been associated with the development of McCune-Albright syndrome, involving the cAMP pathway-associated G-protein, Gsα. The various tissues involved in the syndrome is a result of the ubiquitous signaling of Gsα.
*The [[GNAS1|GNAS]] gene mutation has been associated with the development of McCune-Albright syndrome, involving the [[Cyclic adenosine monophosphate|cAMP]] pathway-associated G-protein, [[Gsα]]. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>


==Causes==
==Causes==


McCune-Albright syndrome is caused by a missense mutation of the GNAS gene alpha subunit which becomes constitutively activated. This increases intracellular cAMP which activates downstream hormones resulting in multiple tissue types being affected and mosaicism presented in its patients. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
McCune-Albright syndrome is caused by a [[missense mutation]] of the [[GNAS1|GNAS]] gene alpha subunit which becomes constitutively activated. This increases intracellular [[Cyclic adenosine monophosphate|cAMP]] which activates downstream [[Hormone|hormones]] resulting in multiple [[tissue]] types being affected and [[mosaicism]] presented in its patients. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>


==Differentiating McCune-Albright syndrome from other Diseases==
==Differentiating McCune-Albright syndrome from other Diseases==


For further information about the differential diagnosis, [[McCune-Albright Differential Diagnosis|click here]]
McCune-Albright syndrome must be differentiated from [[Neurofibromatosis]], isolated [[fibrous dysplasia]] and other causes of [[precocious puberty]].
 
*[[Neurofibromatosis]] and McCune-Albright syndrome both have [[Café au lait spot|café au lait]] macules. However, [[neurofibromatosis]] [[Macule|macules]] have smooth borders with McCune-Albright being irregular. <ref name="pmid31196103">{{cite journal| author=Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A | display-authors=etal| title=Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. | journal=Orphanet J Rare Dis | year= 2019 | volume= 14 | issue= 1 | pages= 139 | pmid=31196103 | doi=10.1186/s13023-019-1102-9 | pmc=6567644 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31196103  }} </ref>
*Neurfibromatosis would also have the additional sign of [[Neurofibroma|neurofibromas]],<ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>  optic [[Glioma|gliomas]], iris [[hamartomas]], and axillary freckling.<ref name="pmid10699117">{{cite journal| author=DeBella K, Szudek J, Friedman JM| title=Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. | journal=Pediatrics | year= 2000 | volume= 105 | issue= 3 Pt 1 | pages= 608-14 | pmid=10699117 | doi=10.1542/peds.105.3.608 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10699117  }} </ref>
*The absence of endocrinopathies and [[café au lait macules]] would differentiate MAS from [[isolated fibrous dysplasia]].<ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>


==Epidemiology and Demographics==
==Epidemiology and Demographics==
*The prevalence of McCune-Albright syndrome is between 1:100,000 and 1:1,000,000 making it very rare.  
 
===Prevalence===
 
*The [[prevalence]] of McCune-Albright syndrome is between 1:100,000 and 1:1,000,000 making it very rare. <ref name="pmid15126527">{{cite journal| author=Lumbroso S, Paris F, Sultan C, European Collaborative Study| title=Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study. | journal=J Clin Endocrinol Metab | year= 2004 | volume= 89 | issue= 5 | pages= 2107-13 | pmid=15126527 | doi=10.1210/jc.2003-031225 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15126527  }} </ref>
 
===Age===
===Age===
*McCune-Albright syndrome is more commonly observed among infants and young children.
 
*McCune-Albright syndrome is more commonly observed among infants and young children. <ref name="pmid15126527">{{cite journal| author=Lumbroso S, Paris F, Sultan C, European Collaborative Study| title=Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study. | journal=J Clin Endocrinol Metab | year= 2004 | volume= 89 | issue= 5 | pages= 2107-13 | pmid=15126527 | doi=10.1210/jc.2003-031225 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15126527  }} </ref>


===Gender===
===Gender===
*McCune-Albright syndrome affects boys and girls equally. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume= | issue= | pages= | pmid=25719192 | doi= | pmc= | url= }} </ref>
 
*Girls are more commonly affected with McCune-Albright syndrome than boys. <ref name="pmid15126527">{{cite journal| author=Lumbroso S, Paris F, Sultan C, European Collaborative Study| title=Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study. | journal=J Clin Endocrinol Metab | year= 2004 | volume= 89 | issue= 5 | pages= 2107-13 | pmid=15126527 | doi=10.1210/jc.2003-031225 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15126527  }} </ref>
 
===Race===
===Race===
*There is no racial predilection for McCune-Albright syndrome.
 
*There is no racial predilection for McCune-Albright syndrome. <ref name="pmid15126527">{{cite journal| author=Lumbroso S, Paris F, Sultan C, European Collaborative Study| title=Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study. | journal=J Clin Endocrinol Metab | year= 2004 | volume= 89 | issue= 5 | pages= 2107-13 | pmid=15126527 | doi=10.1210/jc.2003-031225 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15126527  }} </ref>


==Risk Factors==
==Risk Factors==
Line 52: Line 55:


==Natural History, Complications and Prognosis==
==Natural History, Complications and Prognosis==
*Early clinical features include café-au-lait macules often shortly after or at birth.
 
*If left untreated patients may progress to develop decreased adult stature as a result of precocious puberty. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume= | issue= | pages= | pmid=30725777 | doi= | pmc= | url= }} </ref>
*Early clinical features include [[café-au-lait macules]] often at birth. <ref name="pmid31865341">{{cite journal| author=Spencer T, Pan KS, Collins MT, Boyce AM| title=The Clinical Spectrum of McCune-Albright Syndrome and Its Management. | journal=Horm Res Paediatr | year= 2019 | volume= 92 | issue= 6 | pages= 347-356 | pmid=31865341 | doi=10.1159/000504802 | pmc=7302983 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31865341  }} </ref>
*Common complications of McCune-Albright syndrome include rickets because of phosphate wasting and pain and fractures at fibrous dysplasia sites. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
*If left untreated, patients may progress to develop decreased adult [[stature]] as a result of [[precocious puberty]].
*Common complications of McCune-Albright syndrome include [[rickets]] because of [[Phosphate|phosphate wasting]] and [[fractures]] at [[fibrous dysplastic]] sites. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>


==Diagnosis==
==Diagnosis==
Line 61: Line 65:


*The diagnosis of McCune-Albright syndrome is a clinical diagnosis. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
*The diagnosis of McCune-Albright syndrome is a clinical diagnosis. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
*Though there are genetic tests available for the GNAS gene mutation with new PCR techniques for those who show clinical signs of the syndrome.  
*Though there are genetic tests available for the GNAS gene mutation with new [[Polymerase chain reaction|PCR]] techniques for those who show clinical signs of the syndrome. <ref name="pmid28520344">{{cite journal| author=Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL | display-authors=etal| title=Medical Genetics Summaries | journal= | year= 2012 | volume=  | issue=  | pages=  | pmid=28520344 | doi= | pmc= | url= }} </ref>
*Patients who present with monostotic fibrous dysplasia are required to have evidence of the pathogenic GNAS gene my molecular testing <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
*Patients who present with [[Monostotic fibrous dysplasia|monostotic]] fibrous dysplasia are required to have evidence of the pathogenic [[GNAS1|GNAS]] gene by molecular testing. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>


===Symptoms===
===Symptoms===
{| align=right
|-
|
[[Image:Cafe_au_lait_McCune_Albright.jpg|frame|Café au lait spot in McCune Albright syndrome with coast of Maine irregular borders]]
|}


*Symptoms of McCune-Albright syndrome include the following:
*Symptoms of McCune-Albright syndrome include the following:
**Precocious puberty
**[[Precocious puberty]] being the most common presentation. <ref name="pmid10614538">{{cite journal| author=de Sanctis C, Lala R, Matarazzo P, Balsamo A, Bergamaschi R, Cappa M | display-authors=etal| title=McCune-Albright syndrome: a longitudinal clinical study of 32 patients. | journal=J Pediatr Endocrinol Metab | year= 1999 | volume= 12 | issue= 6 | pages= 817-26 | pmid=10614538 | doi=10.1515/jpem.1999.12.6.817 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10614538  }} </ref>
***In girls presenting with ovarian cysts with vaginal bleeding and breast development
***In girls presenting with recurrent [[Cyst|cysts]] and cyclic [[Menstruation|menses]]. <ref name="pmid1614755">{{cite journal| author=Frisch LS, Copeland KC, Boepple PA| title=Recurrent ovarian cysts in childhood: diagnosis of McCune-Albright syndrome by bone scan. | journal=Pediatrics | year= 1992 | volume= 90 | issue= 1 Pt 1 | pages= 102-4 | pmid=1614755 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1614755  }} </ref>
***In boys presenting with acne, body odor, pubic hair and penile enlargement <ref name="pmid28520344">{{cite journal| author=Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL | display-authors=etal| title=Medical Genetics Summaries | journal= | year= 2012 | volume= | issue= | pages= | pmid=28520344 | doi= | pmc= | url= }} </ref>
***In boys presenting with [[acne]], body odor, pubic hair and penile enlargement.
***Both genders with gonadal pathologies <ref name="pmid28520344">{{cite journal| author=Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL | display-authors=etal| title=Medical Genetics Summaries | journal= | year= 2012 | volume=  | issue=  | pages=  | pmid=28520344 | doi= | pmc= | url= }} </ref>
***Both genders with gonadal pathologies. <ref name="pmid28520344">{{cite journal| author=Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL | display-authors=etal| title=Medical Genetics Summaries | journal= | year= 2012 | volume=  | issue=  | pages=  | pmid=28520344 | doi= | pmc= | url= }} </ref>
**Fibrous dysplasia leading to pathologic fractures or pain <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref> because of fibrous tissue replacing the normal bone <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
**Fibrous dysplasia leading to pathologic [[fractures]] or pain <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref> because of [[Fibrous connective tissue|fibrous tissue]] replacing the normal [[bone]].
***This can be either monostotic (involving one bone) or polyostotic (involving multiple bones) <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume= | issue= | pages= | pmid=25719192 | doi= | pmc= | url= }} </ref>
***This can be either [[Monostotic fibrous dysplasia|monostotic]] (involving one bone) or polyostotic (involving multiple bones). <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
**Café au lait spots with “coast of Maine” irregular borders <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume= | issue= | pages= | pmid=30725777 | doi= | pmc= | url= }} </ref> and are often the first presenting sign <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
***This presents in adolescent years affecting males more than females. <ref name="pmid11856945">{{cite journal| author=Biermann JS| title=Common benign lesions of bone in children and adolescents. | journal=J Pediatr Orthop | year= 2002 | volume= 22 | issue= 2 | pages= 268-73 | pmid=11856945 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11856945  }} </ref>
**Possible hyperthyroidism, Cushing syndrome, acromegaly or prolactin secretion due to increased thyroid, cortisol, growth hormone or prolactin secretion respectively depending on which tissues are affected <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
**[[Café au lait spots]] with “coast of Maine” irregular borders. <ref name="pmid24671640">{{cite journal| author=Pichard DC, Boyce AM, Collins MT, Cowen EW| title=Oral pigmentation in McCune-Albright syndrome. | journal=JAMA Dermatol | year= 2014 | volume= 150 | issue= 7 | pages= 760-3 | pmid=24671640 | doi=10.1001/jamadermatol.2014.184 | pmc=4933654 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24671640  }} </ref> are often the first presenting sign <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref> and may increase over time. <ref name="pmid17848252">{{cite journal| author=Nabhan ZM, West KW, Eugster EA| title=Oophorectomy in McCune-Albright syndrome: a case of mistaken identity. | journal=J Pediatr Surg | year= 2007 | volume= 42 | issue= 9 | pages= 1578-83 | pmid=17848252 | doi=10.1016/j.jpedsurg.2007.04.021 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17848252  }} </ref>
**Phosphate wasting with or without hypophosphatemia <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref> mediated by Fibroblast growth factor 23 (FGF23) <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume= | issue= | pages= | pmid=25719192 | doi= | pmc= | url= }} </ref>
**Possible [[hyperthyroidism]], [[Cushing's syndrome|Cushing]] syndrome, [[acromegaly]] or [[prolactin]] secretion due to increased [[thyroid]], [[cortisol]], [[growth hormone]] or [[prolactin]] secretion respectively depending on which [[tissues]] are affected. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
**[[Phosphate]] wasting with or without [[hypophosphatemia]] mediated by [[Fibroblast growth factor 23]] (FGF23). <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
**Possible [[hepatitis]], [[cholestasis]] and cardiac [[Cardiac arrhythmia|arrhythmias]]. <ref name="pmid31196103">{{cite journal| author=Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A | display-authors=etal| title=Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. | journal=Orphanet J Rare Dis | year= 2019 | volume= 14 | issue= 1 | pages= 139 | pmid=31196103 | doi=10.1186/s13023-019-1102-9 | pmc=6567644 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31196103  }} </ref>
 
[[Image:Cafe au lait (with MR, it's McCune Albright).jpg|frame|Café au lait spot]]


===Physical Examination===
===Physical Examination===
*Patients with McCune-Albright syndrome usually present with bone pain or limping.
 
*Physical examination may be remarkable for:
*Patients with McCune-Albright syndrome usually present with [[bone pain]] or limping.
**Facial asymmetry due to craniofacial fibrous dysplasia
*Physical examination may be remarkable for:<ref name="pmid31865341">{{cite journal| author=Spencer T, Pan KS, Collins MT, Boyce AM| title=The Clinical Spectrum of McCune-Albright Syndrome and Its Management. | journal=Horm Res Paediatr | year= 2019 | volume= 92 | issue= 6 | pages= 347-356 | pmid=31865341 | doi=10.1159/000504802 | pmc=7302983 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31865341  }} </ref>
**Hearing impairment or visual disturbances due to craniofacial fibrous dysplasia
**Facial asymmetry due to craniofacial fibrous dysplasia.
**Café au lait macules
**[[Hearing impairment]] or [[visual disturbances]] due to craniofacial fibrous dysplasia.
**Goiter due to hyperthyroidism
**[[Café au lait spot|Café au lait macules]].
**Macrocephaly due to excess growth hormone
**[[Goiter]] due to [[hyperthyroidism]].
**Vaginal bleeding in females due to ovarian cysts
**[[Macrocephaly]] due to excess growth hormone.
**Pubic and or axillary hair and penile enlargement in males
**[[Vaginal bleeding]] in females due to [[Ovarian cyst|ovarian cysts]].
**Growth acceleration in both genders
**Pubic and or axillary hair and penile enlargement in males.
**Cushingoid features due to hypercortisolism  
**Growth acceleration in both genders.
**Cushingoid features due to [[Cushing's syndrome|hypercortisolism]].


===Laboratory Findings===
===Laboratory Findings===


*Girls will have raised estradiol levels indicating an activated hypothalamic-pituitary axis.  
*Girls will have raised [[estradiol]] levels indicating an activated [[hypothalamic-pituitary axis]].
*Other laboratory findings consistent with the diagnosis of McCune-Albright syndrome are elevated growth hormone which can be deduced by an oral glucose tolerance test, serum GH and prolactin measurements.
*Other laboratory findings consistent with the diagnosis of McCune-Albright syndrome are elevated [[growth hormone]] which can be deduced by an [[oral glucose tolerance test]], serum GH and [[prolactin]] measurements.
*Evaluation of hyperthyroidism is indicated by measuring TSH, free and bound thyroxine and T3. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
*Evaluation of [[hyperthyroidism]] by measuring [[TSH]], free and bound [[thyroxine]] and [[T3]]. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>


===Electrocardiogram===
===Electrocardiogram===
Line 110: Line 114:
===Echocardiography or Ultrasound===
===Echocardiography or Ultrasound===


US in boys may be helpful in the diagnosis of McCune-Albright syndrome. Findings on an US suggestive of McCune-Albright syndrome include testicular ultrasounds to identify hormonally active tumors.<ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
US in boys may be helpful in the diagnosis of McCune-Albright syndrome. Findings on an US suggestive of McCune-Albright syndrome include testicular ultrasounds to detect hormonally active tumors.<ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>


===CT scan===
===CT scan===


CT scan may be helpful in the diagnosis of McCune-Albright syndrome. Findings on CT scan suggestive of/diagnostic of McCune-Albright syndrome include fibroblastic lesions. It is helpful to identify these early in children to prevent permanent deformities. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
[[Computed tomography|CT scan]] may be helpful in the diagnosis of McCune-Albright syndrome. Findings on CT scan suggestive of/diagnostic of McCune-Albright syndrome include [[Fibroblast|fibroblastic]] lesions. It is helpful to identify these early in children to prevent permanent deformities. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>


===MRI===
===MRI===
Line 123: Line 127:


===Other Diagnostic Studies===
===Other Diagnostic Studies===
*McCune Albright may be diagnosed using total body bone scintigraphy to identify the fibrous dysplastic lesions. This should then be followed up with radiographs and CT to clearly determine the extent of the lesions. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
 
*It is helpful to perform baseline ophthalmic and audiologic testing for those patients whose fibrous dysplastic lesions involve the craniofacial area <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
*McCune Albright may be diagnosed using total body bone [[scintigraphy]] to identify the fibrous dysplastic lesions. This should then be followed up with radiographs and CT to clearly determine the extent of the lesions.
*It is helpful to perform baseline ophthalmic and audiologic testing for those patients whose fibrous dysplastic lesions involve the craniofacial area. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>


==Treatment==
==Treatment==


===Medical Therapy===
===Medical Therapy===
*The treatment for McCune Albright syndrome includes:
*The treatment for McCune Albright syndrome includes:
**Precocious puberty- treatment is aimed to prevent bone age advancement <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
**Precocious puberty- treatment is aimed to prevent bone age advancement. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
***For girls- Letrozole (aromatase inhibitor) and or tamoxifen (estrogen receptor modulator) <ref name="pmid28520344">{{cite journal| author=Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL | display-authors=etal| title=Medical Genetics Summaries | journal= | year= 2012 | volume=  | issue=  | pages=  | pmid=28520344 | doi= | pmc= | url= }} </ref>
***For girls- [[Letrozole]] ([[Aromatase inhibitors|aromatase inhibitor]]) and or [[tamoxifen]] ([[estrogen]] receptor modulator). <ref name="pmid28520344">{{cite journal| author=Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL | display-authors=etal| title=Medical Genetics Summaries | journal= | year= 2012 | volume=  | issue=  | pages=  | pmid=28520344 | doi= | pmc= | url= }} </ref>
***For boys- treatment options are less well established <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
***For boys- treatment options are not well established.
**Fibrous dysplasia – treatment is aimed to minimize morbidity related to pain and fractures: <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
**Fibrous dysplasia – treatment is aimed to minimize pain and fractures:  
***Bisphosphonates such as zoledronic acid and pamidronate <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref> have been used for fibrous dysplasia pain. <ref name="pmid28520344">{{cite journal| author=Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL | display-authors=etal| title=Medical Genetics Summaries | journal= | year= 2012 | volume=  | issue=  | pages=  | pmid=28520344 | doi= | pmc= | url= }} </ref>
***[[Bisphosphonate|Bisphosphonates]] such as [[Zoledronic Acid|zoledronic]] acid and [[pamidronate]] <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref> have been used for fibrous dysplasia pain. <ref name="pmid28520344">{{cite journal| author=Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL | display-authors=etal| title=Medical Genetics Summaries | journal= | year= 2012 | volume=  | issue=  | pages=  | pmid=28520344 | doi= | pmc= | url= }} </ref>
**Endocrinopathies  
**Endocrinopathies:
***Thyroid disease – Methimazole is effective though surgery is preferred <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
***Thyroid disease – [[Methimazole]] is effective though surgery is preferred.
***Increased growth hormone  
***Increased growth hormone:
****Octeotride which acts as a somatostatin analog and should be monitored for signs and symptoms of gallbladder disease <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
****[[Octreotride]] which acts as a [[somatostatin]] analog and should be monitored for signs and symptoms of [[gallbladder]] disease.
****Pegvisomant which is a growth hormone receptor antagonist and should be monitored for hepatotoxicity <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
****[[Pegvisomant]] which is a growth hormone receptor antagonist and should be monitored for [[hepatotoxicity]].
***Hypercortisolism - metyparone is effective
***[[Cushing's syndrome|Hypercortisolism]] - metyparone is effective.
***FGF23-mediated phosphate wasting with oral phosphorus and calcitriol <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume= | issue= | pages= | pmid=25719192 | doi= | pmc= | url= }} </ref>
***FGF23-mediated [[phosphate]] wasting with oral phosphorus and [[Calcitriol (oral)|calcitriol]]. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
**[[Café-au-lait macules]]:
***There is no effective treatment <ref name="pmid21272121">{{cite journal| author=Ozawa T, Tateishi C, Shirakawa M, Murakami E, Ishii M, Harada T| title=Long-term follow-up of a case of cheek hyperpigmentation associated with McCune-Albright syndrome treated with Q-switched ruby laser. | journal=Dermatol Surg | year= 2011 | volume= 37 | issue= 2 | pages= 263-6 | pmid=21272121 | doi=10.1111/j.1524-4725.2010.01864.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21272121  }} </ref>


===Surgery===
===Surgery===
*Surgery should be used in extreme caution for female patients with ovarian cysts because of the high risk of recurrence and resultant decrease in ovarian reserve. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
 
*Patients with hyperthyroidism are preferred to have a thyroidectomy with total gland resection <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
*Surgery should be used in extreme caution for female patients with [[Ovarian cyst|ovarian cysts]] because of the high risk of recurrence and resultant decrease in ovarian reserve.
*Patients with [[hyperthyroidism]] are preferred to have a [[thyroidectomy]] with total gland resection. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>


===Prevention===
===Prevention===
*Once diagnosed patients with McCune-Albright syndrome are followed-up with:
 
**Females – early breast cancer screening <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
*Once diagnosed, patients with McCune-Albright syndrome are followed-up with:
**Males – testicular lesions by physical examination and US <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
**Females – early [[breast cancer screening]].
**Both genders – signs of precocious puberty, growth hormone excess or growth acceleration (IGF-1 levels), monitoring thyroid function (TSH, free T4, and T3), routine radiographs for fibrous dysplasia lesions particularly to check for scoliosis, serum phosphorous to monitor for development of hypophosphatemia <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref> and annual vision and hearing testing to monitor fibrotic lesions affecting these areas. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
**Males – testicular lesions by physical examination and US. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
**Parents should be counseled that McCune-Albright syndrome is not inherited <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
**Both genders – signs of [[precocious puberty]], [[growth hormone]] excess or growth acceleration ([[Insulin-like growth factor-I|IGF-1]] levels), monitoring thyroid function ([[TSH]], free [[T4]], and [[T3]]), routine radiographs for fibrous dysplasia lesions particularly to check for [[scoliosis]], serum phosphorous to monitor for development of [[hypophosphatemia]] <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref> and annual vision and hearing testing to monitor fibrotic lesions affecting these areas. <ref name="pmid30725777">{{cite journal| author=| title=StatPearls | journal= | year= 2020 | volume=  | issue=  | pages=  | pmid=30725777 | doi= | pmc= | url= }} </ref>
*There is an increased risk for malignancies and it is advised to minimize radiation exposure and monitor patients regularly. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume= | issue=  | pages= | pmid=25719192 | doi= | pmc= | url= }} </ref>
*Parents should be counseled that McCune-Albright syndrome is not inherited. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
*Patients should also be advised to avoid contact sports and optic nerve decompressions <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>
*There is an increased risk for [[Cancer|malignancies]]. <ref name="pmid17982395">{{cite journal| author=Chanson P, Salenave S, Orcel P| title=McCune-Albright syndrome in adulthood. | journal=Pediatr Endocrinol Rev | year= 2007 | volume= 4 Suppl 4 | issue=  | pages= 453-62 | pmid=17982395 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17982395  }} </ref>
*Patients should also be advised to avoid contact sports and [[optic nerve]] decompressions. <ref name="pmid25719192">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume=  | issue=  | pages=  | pmid=25719192 | doi= | pmc= | url= }} </ref>


==References==
==References==
Line 160: Line 170:


==See also==
==See also==
* [[Fibrous dysplasia]]
 
* [[Precocious puberty]]
*[[Fibrous dysplasia]]
* [[Café au lait spot]]
*[[Precocious puberty]]
*[[Café au lait spot]]


==External links==
==External links==
* [http://www.medterms.com/script/main/art.asp?articlekey=11362 Medterms.com]
 
* [http://www.le.ac.uk/genetics/maa7/GNAS1/ GNAS gene]
*[http://www.medterms.com/script/main/art.asp?articlekey=11362 Medterms.com]
* [http://www.rarediseases.org/search/rdbdetail_abstract.html?disname=McCune%20Albright%20Syndrome NORD]
*[http://www.le.ac.uk/genetics/maa7/GNAS1/ GNAS gene]
*[http://www.rarediseases.org/search/rdbdetail_abstract.html?disname=McCune%20Albright%20Syndrome NORD]


{{Congenital malformations and deformations of musculoskeletal system}}
{{Congenital malformations and deformations of musculoskeletal system}}

Latest revision as of 21:08, 21 October 2020


WikiDoc Resources for McCune-Albright syndrome

Articles

Most recent articles on McCune-Albright syndrome

Most cited articles on McCune-Albright syndrome

Review articles on McCune-Albright syndrome

Articles on McCune-Albright syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on McCune-Albright syndrome

Images of McCune-Albright syndrome

Photos of McCune-Albright syndrome

Podcasts & MP3s on McCune-Albright syndrome

Videos on McCune-Albright syndrome

Evidence Based Medicine

Cochrane Collaboration on McCune-Albright syndrome

Bandolier on McCune-Albright syndrome

TRIP on McCune-Albright syndrome

Clinical Trials

Ongoing Trials on McCune-Albright syndrome at Clinical Trials.gov

Trial results on McCune-Albright syndrome

Clinical Trials on McCune-Albright syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on McCune-Albright syndrome

NICE Guidance on McCune-Albright syndrome

NHS PRODIGY Guidance

FDA on McCune-Albright syndrome

CDC on McCune-Albright syndrome

Books

Books on McCune-Albright syndrome

News

McCune-Albright syndrome in the news

Be alerted to news on McCune-Albright syndrome

News trends on McCune-Albright syndrome

Commentary

Blogs on McCune-Albright syndrome

Definitions

Definitions of McCune-Albright syndrome

Patient Resources / Community

Patient resources on McCune-Albright syndrome

Discussion groups on McCune-Albright syndrome

Patient Handouts on McCune-Albright syndrome

Directions to Hospitals Treating McCune-Albright syndrome

Risk calculators and risk factors for McCune-Albright syndrome

Healthcare Provider Resources

Symptoms of McCune-Albright syndrome

Causes & Risk Factors for McCune-Albright syndrome

Diagnostic studies for McCune-Albright syndrome

Treatment of McCune-Albright syndrome

Continuing Medical Education (CME)

CME Programs on McCune-Albright syndrome

International

McCune-Albright syndrome en Espanol

McCune-Albright syndrome en Francais

Business

McCune-Albright syndrome in the Marketplace

Patents on McCune-Albright syndrome

Experimental / Informatics

List of terms related to McCune-Albright syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD

Overview

McCune-Albright syndrome is a rare genetic disorder caused by an activating mutation of the GNAS gene resulting in various phenotypic presentations. McCune-Albright syndrome typically presents with the triad of fibrous dysplasia, precocious puberty and café au lait spots in both genders. Other manifestations include acromegaly, Cushing’s syndrome and thyroid hyperplasia or toxic nodular goiters.

Historical Perspective

Classification

There is no established system for the classification of McCune-Albright syndrome.

Pathophysiology

Causes

McCune-Albright syndrome is caused by a missense mutation of the GNAS gene alpha subunit which becomes constitutively activated. This increases intracellular cAMP which activates downstream hormones resulting in multiple tissue types being affected and mosaicism presented in its patients. [2]

Differentiating McCune-Albright syndrome from other Diseases

McCune-Albright syndrome must be differentiated from Neurofibromatosis, isolated fibrous dysplasia and other causes of precocious puberty.

Epidemiology and Demographics

Prevalence

  • The prevalence of McCune-Albright syndrome is between 1:100,000 and 1:1,000,000 making it very rare. [6]

Age

  • McCune-Albright syndrome is more commonly observed among infants and young children. [6]

Gender

  • Girls are more commonly affected with McCune-Albright syndrome than boys. [6]

Race

  • There is no racial predilection for McCune-Albright syndrome. [6]

Risk Factors

There are no risk factors for McCune-Albright syndrome.

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

  • The diagnosis of McCune-Albright syndrome is a clinical diagnosis. [2]
  • Though there are genetic tests available for the GNAS gene mutation with new PCR techniques for those who show clinical signs of the syndrome. [8]
  • Patients who present with monostotic fibrous dysplasia are required to have evidence of the pathogenic GNAS gene by molecular testing. [3]

Symptoms

Café au lait spot

Physical Examination

Laboratory Findings

Electrocardiogram

There are no ECG findings associated with McCune-Albright syndrome.

X-ray

The fibrous dysplasia of bone is present at multiple sites (polyostotic) and xrays would give a ground glass appearance. [8]

Echocardiography or Ultrasound

US in boys may be helpful in the diagnosis of McCune-Albright syndrome. Findings on an US suggestive of McCune-Albright syndrome include testicular ultrasounds to detect hormonally active tumors.[2]

CT scan

CT scan may be helpful in the diagnosis of McCune-Albright syndrome. Findings on CT scan suggestive of/diagnostic of McCune-Albright syndrome include fibroblastic lesions. It is helpful to identify these early in children to prevent permanent deformities. [2]

MRI

There are no MRI findings associated with McCune-Albright syndrome.

Other Imaging Findings

There are no other imaging findings associated with McCune-Albright syndrome.

Other Diagnostic Studies

  • McCune Albright may be diagnosed using total body bone scintigraphy to identify the fibrous dysplastic lesions. This should then be followed up with radiographs and CT to clearly determine the extent of the lesions.
  • It is helpful to perform baseline ophthalmic and audiologic testing for those patients whose fibrous dysplastic lesions involve the craniofacial area. [3]

Treatment

Medical Therapy

Surgery

  • Surgery should be used in extreme caution for female patients with ovarian cysts because of the high risk of recurrence and resultant decrease in ovarian reserve.
  • Patients with hyperthyroidism are preferred to have a thyroidectomy with total gland resection. [3]

Prevention

  • Once diagnosed, patients with McCune-Albright syndrome are followed-up with:
    • Females – early breast cancer screening.
    • Males – testicular lesions by physical examination and US. [3]
    • Both genders – signs of precocious puberty, growth hormone excess or growth acceleration (IGF-1 levels), monitoring thyroid function (TSH, free T4, and T3), routine radiographs for fibrous dysplasia lesions particularly to check for scoliosis, serum phosphorous to monitor for development of hypophosphatemia [3] and annual vision and hearing testing to monitor fibrotic lesions affecting these areas. [2]
  • Parents should be counseled that McCune-Albright syndrome is not inherited. [3]
  • There is an increased risk for malignancies. [15]
  • Patients should also be advised to avoid contact sports and optic nerve decompressions. [3]

References

  1. ↑ Manring MM, Calhoun JH (2011). "Biographical sketch: Fuller Albright, MD 1900-1969". Clin Orthop Relat Res. 469 (8): 2092–5. doi:10.1007/s11999-011-1831-0. PMC 3126964. PMID 21384213.
  2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 "StatPearls". 2020. PMID 30725777.
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K; et al. (1993). "GeneReviews®". PMID 25719192.
  4. ↑ 4.0 4.1 Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A; et al. (2019). "Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium". Orphanet J Rare Dis. 14 (1): 139. doi:10.1186/s13023-019-1102-9. PMC 6567644 Check |pmc= value (help). PMID 31196103.
  5. ↑ DeBella K, Szudek J, Friedman JM (2000). "Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children". Pediatrics. 105 (3 Pt 1): 608–14. doi:10.1542/peds.105.3.608. PMID 10699117.
  6. ↑ 6.0 6.1 6.2 6.3 Lumbroso S, Paris F, Sultan C, European Collaborative Study (2004). "Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study". J Clin Endocrinol Metab. 89 (5): 2107–13. doi:10.1210/jc.2003-031225. PMID 15126527.
  7. ↑ 7.0 7.1 Spencer T, Pan KS, Collins MT, Boyce AM (2019). "The Clinical Spectrum of McCune-Albright Syndrome and Its Management". Horm Res Paediatr. 92 (6): 347–356. doi:10.1159/000504802. PMC 7302983 Check |pmc= value (help). PMID 31865341.
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL; et al. (2012). "Medical Genetics Summaries". PMID 28520344.
  9. ↑ de Sanctis C, Lala R, Matarazzo P, Balsamo A, Bergamaschi R, Cappa M; et al. (1999). "McCune-Albright syndrome: a longitudinal clinical study of 32 patients". J Pediatr Endocrinol Metab. 12 (6): 817–26. doi:10.1515/jpem.1999.12.6.817. PMID 10614538.
  10. ↑ Frisch LS, Copeland KC, Boepple PA (1992). "Recurrent ovarian cysts in childhood: diagnosis of McCune-Albright syndrome by bone scan". Pediatrics. 90 (1 Pt 1): 102–4. PMID 1614755.
  11. ↑ Biermann JS (2002). "Common benign lesions of bone in children and adolescents". J Pediatr Orthop. 22 (2): 268–73. PMID 11856945.
  12. ↑ Pichard DC, Boyce AM, Collins MT, Cowen EW (2014). "Oral pigmentation in McCune-Albright syndrome". JAMA Dermatol. 150 (7): 760–3. doi:10.1001/jamadermatol.2014.184. PMC 4933654. PMID 24671640.
  13. ↑ Nabhan ZM, West KW, Eugster EA (2007). "Oophorectomy in McCune-Albright syndrome: a case of mistaken identity". J Pediatr Surg. 42 (9): 1578–83. doi:10.1016/j.jpedsurg.2007.04.021. PMID 17848252.
  14. ↑ Ozawa T, Tateishi C, Shirakawa M, Murakami E, Ishii M, Harada T (2011). "Long-term follow-up of a case of cheek hyperpigmentation associated with McCune-Albright syndrome treated with Q-switched ruby laser". Dermatol Surg. 37 (2): 263–6. doi:10.1111/j.1524-4725.2010.01864.x. PMID 21272121.
  15. ↑ Chanson P, Salenave S, Orcel P (2007). "McCune-Albright syndrome in adulthood". Pediatr Endocrinol Rev. 4 Suppl 4: 453–62. PMID 17982395.

See also

External links

it:Sindrome di McCune-Albright-Sternberg

Template:WH Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=McCune-Albright_syndrome&oldid=1670315"